Mangoceuticals targets avian flu with water-based solution

DALLAS - Mangoceuticals, Inc. (NASDAQ: MGRX), a health solutions company with a market capitalization of $11.32 million and impressive year-to-date returns of 82.64% according to InvestingPro, is advancing research into respiratory illness prevention, focusing on a novel approach to combat avian influenza (H5N1) in the poultry industry. The company has partnered with Vipragen Biosciences, an Indian Contract Research Organization, to conduct efficacy studies on antiviral technology acquired from IntraMont Technologies, Inc.

Phase I animal studies have shown promising results in reducing lung viral load, leading to the initiation of Phase II studies. While the company maintains strong gross profit margins of 58.6%, InvestingPro data indicates it’s quickly burning through cash, making these developments crucial for future growth. Mangoceuticals is also exploring the application of this technology in poultry drinking water, aiming to prevent avian flu infections. This approach utilizes Generally Recognized as Safe (GRAS) ingredients, potentially offering a non-pharmaceutical alternative to traditional vaccines and treatments.

The ongoing avian flu outbreak has led to significant economic losses, with over 148 million birds culled in the United States since 2022, causing egg prices to skyrocket. Mangoceuticals’ water-based antiviral solution could provide a cost-effective and scalable preventive measure for poultry farmers, potentially revolutionizing disease prevention in livestock.

With revenue growth of 52.2% in the last twelve months and 11 additional key insights available on InvestingPro, Jacob Cohen, CEO of Mangoceuticals, expressed optimism about the technology’s potential to integrate seamlessly into current farming practices and alleviate financial burdens on farmers. The company plans to share final study results after completion and prior to commercialization, ensuring intellectual property protection.

Mangoceuticals, also known as MangoRx, is known for developing men’s health and wellness products through a telemedicine platform, focusing on areas such as erectile dysfunction, hair growth, hormone replacement, and weight management. Financial metrics reveal the company’s current ratio of 0.07, indicating potential liquidity challenges as it pursues growth opportunities in multiple markets.

This news is based on a press release statement and contains forward-looking information. The results of the studies are yet to be confirmed, and the company’s expectations may not be realized if the solution does not perform as hoped in further trials.

In other recent news, Mangoceuticals, a telemedicine company, has made several noteworthy advancements. The company has reported progress in its H1N1 efficacy study and has initiated a concurrent study on H5N1, both involving its patented respiratory illness prevention technology. These studies, being conducted by Vipragen Biosciences and Intramont Technologies, have shown promising preliminary results.

Additionally, Mangoceuticals has also undergone significant changes to its corporate structure, introducing a new class of Series A Super Majority Voting Preferred Stock. This move effectively grants majority control over corporate decisions to the Series A Preferred Stock holders.

In other developments, Mangoceuticals has entered into a service agreement with Greentree Financial Group, Inc., issuing 40,000 shares of its restricted common stock to Greentree in exchange for their services. Concurrently, Mangoceuticals disclosed the sale of 75,000 shares of common stock to Platinum Point Capital.

The company has also initiated an investigation into potential stock manipulation following its reverse stock split, due to abnormal trading patterns and a significant increase in shareholder accounts. Lastly, Mangoceuticals has signed a Consulting Agreement with CFO Eugene M. Johnston, who will continue to serve the company for a 12-month period, receiving a monthly payment and a grant of 25,000 shares of Mangoceuticals common stock.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.